Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Nanorobots Could Redefine Targeted Cancer Therapies

XTALKS VITALS NEWS

These researchers have designed nanorobots capable of being injected into a patient’s bloodstream, and delivering a drug directly into cancerous cells.

Tweetables from this article:

Tweet: Nanorobot drug delivery could ensure that only the cancer cells are targeted by the drug http://ctt.ec/1U5yU+Nanorobot drug delivery could ensure that only the cancer cells are targeted by the drug.

Tweet: Nanorobots are able to enter a tumor and autonomically identify the hypoxic zones in tumors http://ctt.ec/O71IT+Nanorobots are able to enter a tumor and autonomically identify the hypoxic zones in tumors.

Share this!

August 17, 2016 | by Sarah Massey, M.Sc.

Targeting tumors using nanorobots could be the future of cancer treatment thanks to research performed at Polytechnique Montréal, Université de Montréal and McGill University. These researchers have designed nanorobots capable of being injected into a patient’s bloodstream, and delivering a drug directly into cancerous cells.

As many chemotherapeutic drugs used today are both cytotoxic to tumor cells and the surrounding healthy tissue, this mode of drug delivery could ensure that only the cancer cells are targeted by the drug. The researchers also believe that these nanorobot agents could reduce the effective dosage necessary, thereby further reducing toxic side-effects of the cancer therapies.

The research – published in the journal, Nature Nanotechnology – was conducted on mice with colorectal tumors. They found that the nanorobots were successful at delivering cancer drugs into the heart of the tumors.

“These legions of nanorobotic agents were actually composed of more than 100 million flagellated bacteria – and therefore self-propelled – and loaded with drugs that moved by taking the most direct path between the drug's injection point and the area of the body to cure,” said Professor Sylvain Martel, the senior author on the paper and holder of the Canada Research Chair in Medical Nanorobotics and Director of the Polytechnique Montréal Nanorobotics Laboratory. “The drug's propelling force was enough to travel efficiently and enter deep inside the tumors.”



One of the most significant challenges in cancer treatment today is in the delivery of drugs into the low-oxygen areas of the tumor, known as hypoxic zones. These areas are caused by increased consumption of oxygen by rapidly dividing tumor cells, and treatments like radiotherapy are ineffective against these hypoxic zones.

The nanorobots on the other hand, are able to enter a tumor and autonomically identify the hypoxic zones. They then release their drug load, essentially destroying the tumor from the inside out.

The nanorobots are able to navigate using a chain of magnetic nanoparticles which attracts them toward a magnetic field. In addition, an oxygen measuring sensor allows the nanotech bacteria to seek out the tumor’s hypoxic zones and remain there.

“This innovative use of nanotransporters will have an impact not only on creating more advanced engineering concepts and original intervention methods, but it also throws the door wide open to the synthesis of new vehicles for therapeutic, imaging and diagnostic agents,” said Martel. “Chemotherapy, which is so toxic for the entire human body, could make use of these natural nanorobots to move drugs directly to the targeted area, eliminating the harmful side effects while also boosting its therapeutic effectiveness.”


Keywords: Nanotechnology, Cancer, Chemotherapy


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Lavazza Acquires Controlling Stake in Canada’s Kicking Horse Coffee

May 26, 2017 - Italian coffee company Lavazza, has secured an 80 percent equity stake in Canadian organic and fair-trade coffee company Kicking Horse Coffee, in a deal worth CAD$215 million.

Featured In: Food News


FDA First: Keytruda Approved for Cancer Treatment Based on Biomarker Alone

May 25, 2017 - For the first time, the FDA has approved a cancer treatment for solid tumors based on the presence of a biomarker, as opposed to specifying a tissue of origin.

Featured In: Biotech News


One Year of Medically Assisted Dying in Canada

May 25, 2017 - In June of 2016, the federal government of Canada passed legislation to legalize medically assisted dying.

Featured In: Life Science News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Top 5 Most Impactful Tweets in Life Sciences During the Last Week

REGISTER FOR THESE WEBINARS

EU IVD Regulation: Top Five Changes for Medical Device Manufacturers to Consider


Thermal Processing Systems for the Food Industry: A Guide to Selecting Thermal Equipment and Technology


Rare Disease & Orphan Drug Development: Cost-Efficient Trial Design to Minimize Cash Burn


eTMF Workflows: Active eTMF to Improve the Quality of Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.